→ PTOAF

Attorney Docket No.:

DEX-0209

Inventors:

Salceda et al.

Serial No.: Filing Date:

09/886,241

Page 3

June 21, 2001

or bodily fluids from a normal human control, wherein a change in determined levels of polynucleotide of SEQ ID NO:4, native mRNA encoded by a gene comprising SEQ ID NO:4 or a polynucleotide a naturally occurring allelic variant encoding a polypeptide encoded by SEQ ID NO:4 in said patient versus normal human control is associated with the presence of cancer of the breast, colon, endometrium, kidney, liver, lung, ovary, prostate, small intestine, stomach, testis or uterus.

Claim 4-15 (canceled)

Claim 16: (currently amended) The method of claim 3 wherein the cancer detected is breast cancer.

Claim 17: (new) The method of claim 3 wherein the cancer detected is stomach cancer.

Claim 18: (new) The method of claim 3 wherein the cancer detected is colon cancer.

Claim 19: (new) The method of claim 3 wherein levels of a polynucleotide of SEQ ID NO:4 are determined.

Claim 20: (new) The method of claim 3 wherein levels of native mRNA encoded by a gene comprising SEQ ID NO:4 are determined.

Claim 21: (new) The method of claim 3 wherein levels of a naturally occurring allelic variant encoding a polypeptide

→ PTOAF

Attorney Docket No.:

DEX-0209

Inventors: Serial No.:

Salceda et al.

Filing Date:

09/886,241 June 21, 2001

Page 4

encoded by SEQ ID NO:4 are determined.